- Home
- INMB vs LRMR Comparison
INMB vs LRMR Comparison
Compare INMB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- LRMR
- Stock Information
- Founded
- INMB 2015
- LRMR N/A
- Country
- INMB United States
- LRMR United States
- Employees
- INMB N/A
- LRMR N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- LRMR Health Care
- Exchange
- INMB Nasdaq
- LRMR Nasdaq
- Market Cap
- INMB 176.5M
- LRMR 183.8M
- IPO Year
- INMB 2019
- LRMR N/A
- Fundamental
- Price
- INMB $6.97
- LRMR $2.12
- Analyst Decision
- INMB Strong Buy
- LRMR Strong Buy
- Analyst Count
- INMB 3
- LRMR 9
- Target Price
- INMB $24.33
- LRMR $19.00
- AVG Volume (30 Days)
- INMB 215.6K
- LRMR 1.4M
- Earning Date
- INMB 05-08-2025
- LRMR 04-30-2025
- Dividend Yield
- INMB N/A
- LRMR N/A
- EPS Growth
- INMB N/A
- LRMR N/A
- EPS
- INMB N/A
- LRMR N/A
- Revenue
- INMB $50,000.00
- LRMR N/A
- Revenue This Year
- INMB N/A
- LRMR N/A
- Revenue Next Year
- INMB N/A
- LRMR N/A
- P/E Ratio
- INMB N/A
- LRMR N/A
- Revenue Growth
- INMB N/A
- LRMR N/A
- 52 Week Low
- INMB $4.32
- LRMR $1.61
- 52 Week High
- INMB $11.76
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- INMB 40.42
- LRMR 44.72
- Support Level
- INMB $6.98
- LRMR $2.03
- Resistance Level
- INMB $8.00
- LRMR $2.33
- Average True Range (ATR)
- INMB 0.49
- LRMR 0.30
- MACD
- INMB -0.07
- LRMR -0.01
- Stochastic Oscillator
- INMB 6.59
- LRMR 11.21
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.